(Q33534318)

27 July 2017

1 reference

title

Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings (English)

1 reference

27 July 2017

R Z Litten

1

1 reference

27 July 2017

J P Allen

series ordinal

2

1 reference

27 July 2017

publication date

1 March 1999

1 reference

Journal of Substance Abuse Treatment

27 July 2017

published in

1 reference

27 July 2017

volume

16

1 reference

27 July 2017

issue

2

1 reference

27 July 2017

page(s)

105-112

1 reference

Techniques to enhance compliance with disulfiram

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Pharmacologic Interventions for Alcohol- and Cocaine-Abusing Individuals: A Pilot Study of Disulfiram vs. Naltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Disulfiram treatment of alcoholism

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Molecular and cellular aspects of nicotine abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Disulfiram therapy in patients abusing cocaine and alcohol.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Nicotine vs placebo gum in general medical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Another opiate for the masses?

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Molecular mechanisms of cocaine addiction.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Acamprosate appears to decrease alcohol intake in weaned alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

International update: new findings on promising medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Buprenorphine suppresses heroin use by heroin addicts

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Management of cocaine abuse and dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Myths about the treatment of addiction.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Suppression of psychoactive effects of cocaine by active immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Transdermal nicotine facilitates smoking cessation

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Comparison of buprenorphine and methadone in the treatment of opioid dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Relationship between subjective effects of cocaine and dopamine transporter occupancy

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Naltrexone and alcohol dependence. Role of subject compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Buprenorphine alone and in combination with naloxone in non-dependent humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

Comparison of acamprosate and placebo in long-term treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

A potent and selective endogenous agonist for the mu-opiate receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0740-5472%2898%2900028-2

7 January 2021

10.1016/S0740-5472(98)00028-2

Identifiers

DOI

1 reference

27 July 2017

1 reference